EICHOR
● Completed
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
Condition: Obesity · Overweight · Sponsor: Eli Lilly and Company
About this study
The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction in participants who previously completed treatment with injectable tirzepatide (Zepbound) or injectable semaglutide (Wegovy) in the SURMOUNT-5 trial (NCT05822830).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (29)
| Cahaba Research | Birmingham, Alabama, United States | — |
| Cahaba Research - Pelham | Pelham, Alabama, United States | — |
| Southern California Dermatology, Inc. | Santa Ana, California, United States | — |
| Encompass Clinical Research | Spring Valley, California, United States | — |
| University Clinical Investigators, Inc. | Tustin, California, United States | — |
| New Horizon Research Center | Miami, Florida, United States | — |
| Rophe Adult and Pediatric Medicine/SKYCRNG | Union City, Georgia, United States | — |
| Rocky Mountain Clinical Research | Idaho Falls, Idaho, United States | — |
| Iowa Diabetes and Endocrinology Research Center | West Des Moines, Iowa, United States | — |
| L-MARC Research Center | Louisville, Kentucky, United States | — |
| Arcturus Healthcare , PLC, Troy Internal Medicine Research Division | Troy, Michigan, United States | — |
| Prime Health and Wellness/SKYCRNG | Fayette, Mississippi, United States | — |
+ 17 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06584916